Updating results

1160 results

Sort: Relevance | Date

Laparoscopic surgery for colorectal cancer (TA105)

Evidence-based recommendations on laparoscopic surgery for colorectal (bowel) cancer

Technology appraisal guidance Published August 2006

Methadone and buprenorphine for the management of opioid dependence (TA114)

Evidence-based recommendations on methadone and buprenorphine for the management of opioid dependence

Technology appraisal guidance Published January 2007

Pemetrexed for the treatment of non-small-cell lung cancer (TA124)

Evidence-based recommendations on pemetrexed (Alimta) for treating non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published August 2007

Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer

Technology appraisal guidance Published January 2007 Last updated January 2012

Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

Evidence-based recommendations on docetaxel (Taxotere) for the treatment of hormone-refractory metastatic (advanced) prostate cancer

Technology appraisal guidance Published June 2006

Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)

Evidence-based recommendations on capecitabine (Xeloda) and oxaliplatin (Eloxatin) for adjuvant treatment of stage III (Dukes' C) colon (bowel) cancer

Technology appraisal guidance Published April 2006

Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

Evidence-based recommendations on the use of inhaler systems (devices) for chronic asthma in children under 5

Technology appraisal guidance Published August 2000

Guidance on the Extraction of Wisdom Teeth (TA1)

Evidence-based recommendations on the extraction of wisdom teeth

Technology appraisal guidance Published March 2000

Stapled haemorrhoidopexy for the treatment of haemorrhoids (TA128)

Evidence-based recommendations on stapled haemorrhoidopexy for treating haemorrhoids

Technology appraisal guidance Published September 2007

Infliximab for the treatment of adults with psoriasis (TA134)

Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults

Technology appraisal guidance Published January 2008

Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

Evidence-based recommendations on onhaled corticosteroids for treating chronic asthma in adults and children aged 12 years and over

Technology appraisal guidance Published March 2008

Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)

Evidence-based recommendations using zolpidem and zopiclone (the Z-drugs) for the short-term management of insomnia (sleeplessness) in adults

Technology appraisal guidance Published April 2004

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C

Technology appraisal guidance Published January 2004 Last updated November 2013

Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

Evidence-based recommendations on myocardial perfusion scintigraphy (MPS) for diagnosing and managing angina and myocardial infarction (MI)

Technology appraisal guidance Published November 2003 Last updated July 2011

Guidance on the use of coronary artery stents (TA71)

Evidence-based recommendations on coronary artery stents for treating coronary artery disease (CAD)

Technology appraisal guidance Published October 2003 Last updated July 2008

Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block (TA88)

Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia (slow heart rate) due to sick sinus syndrome and/or atrioventricular block

Technology appraisal guidance Published February 2005 Last updated November 2014

Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

Evidence-based recommendations on imatinib for treating unresectable and/or metastatic gastrointestinal stromal tumours (GIST/soft tissue sarcoma)

Technology appraisal guidance Published October 2004 Last updated November 2010

Laparoscopic surgery for inguinal hernia repair (TA83)

Evidence-based recommendations on laparoscopic (keyhole) surgery for repairing inguinal hernia (hernia in groin)

Technology appraisal guidance Published September 2004

Frequency of application of topical corticosteroids for atopic eczema (TA81)

Evidence-based recommendations on the frequency of application of topical corticosteroids for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)

NICE is unable to make a recommendation about the use in the NHS of Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive…

Technology appraisal guidance Published January 2016

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

Evidence-based recommendations on olaparib (Lynparza)

Technology appraisal guidance Published January 2016

Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Technology appraisal guidance Published January 2016

Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

Evidence-based recommendations on nintedanib (Ofev) for people with idiopathic pulmonary fibrosis.

Technology appraisal guidance Published January 2016

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)

Technology appraisal guidance Published December 2015

Bortezomib for previously untreated mantle cell lymphoma (TA370)

Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults

Technology appraisal guidance Published December 2015

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)

Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)

Technology appraisal guidance Published November 2014

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism

Technology appraisal guidance Published December 2014

Omalizumab for previously treated chronic spontaneous urticaria (TA339)

Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)

Technology appraisal guidance Published June 2015

Secukinumab for treating moderate to severe plaque psoriasis (TA350)

Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis

Technology appraisal guidance Published July 2015

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

Evidence-based recommendations on edoxaban (Lixiana) for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism

Technology appraisal guidance Published August 2015

Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) (TA351)

NICE is unable to make recommendations about the use of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary…

Technology appraisal guidance Published July 2015

Naloxegol for treating opioid‑induced constipation (TA345)

Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation that has had inadequate response to laxatives

Technology appraisal guidance Published July 2015

Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera...

Technology appraisal guidance Published September 2015

Idelalisib for treating chronic lymphocytic leukaemia (TA359)

Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia (CLL) in adults

Technology appraisal guidance Published October 2015

Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)

NICE is unable to make recommendations about the use of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or…

Technology appraisal guidance Published August 2015

Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)

NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..

Technology appraisal guidance Published October 2015

Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C

Technology appraisal guidance Published November 2015

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer before chemotherapy is indicated

Technology appraisal guidance Published January 2016

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

Technology appraisal guidance Published February 2016

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…

Technology appraisal guidance Published February 2016

Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)

Technology appraisal guidance Published August 2014

Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

Technology appraisal guidance Published March 2014

Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

Evidence-based recommendations on enzalutamide (Xtandi) for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen

Technology appraisal guidance Published July 2014

Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)

Evidence-recommendations on erythropoiesis-stimulation agents (epoetin alfa, beta, theta and zeta and darbepoetin alfa) for anaemia in people with cancer..

Technology appraisal guidance Published November 2014

Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)

Evidence-based recommendations on paclitaxel (Taxol) for treating ovarian cancer

Technology appraisal guidance Published January 2003 Last updated May 2005

Guidance on the use of electroconvulsive therapy (TA59)

Evidence-based recommendations on electroconvulsive therapy (ECT) for treating severe depressive illness, mania and catatonia

Technology appraisal guidance Published April 2003 Last updated October 2009

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults

Technology appraisal guidance Published May 2003

Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital

Technology appraisal guidance Published January 2004

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) for some types of chronic hepatitis C

Technology appraisal guidance Published November 2015

Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

Evidence-based recommendations on ramucirumab (Cyramza)

Technology appraisal guidance Published January 2016